Rationale and design of MARQUEE: A phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 5, 2012, Pages 391-395

  Scagliotti, Giorgio V ^a   Novello, Silvia ^a   Schiller, Joan H ^b   Hirsh, Vera ^c   Sequist, Lecia V ^d   Soria, Jean Charles ^e   Von Pawel, Joachim ^f   Schwartz, Brian ^g   Von Roemeling, Reinhard ^h   Sandler, Alan B ⁱ  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Institute Gustave Roussy and University   (France)

^f Asklepios Klinikum Gauting   (Germany)

^g ARQULE INC   (United States)

^h DAIICHI SANKYO INC   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor; Hepatocyte growth factor receptor; MET; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; PLACEBO; SCATTER FACTOR; TIVANTINIB;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; N METHYL N' NITROSO GUANIDINE HUMAN OSTEOSARCOMA TRANSFORMING GENE; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINAZOLINES; QUINOLINES; RESEARCH DESIGN; SALVAGE THERAPY; SURVIVAL RATE;

EID: 84865506979     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.01.003     Document Type: Article

References (19)

1. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
2. G.V. Scagliotti, P. Parikh, J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
3. V.D. Cataldo, D.L. Gibbons, R. Prez-Soler Treatment of non-small-cell lung cancer with erlotinib or gefitinib N Engl J Med 364 2011 947 955
4. P.C. Ma, M.S. Tretiakova, A.C. MacKinnon Expression and mutational analysis of MET in human solid cancers Genes Chromosomes Cancer 47 2008 1025 1037
5. K. Okuda, H. Sasaki, H. Yukiue Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer Cancer Sci 99 2008 2280 2285
6. P.C. Ma, R. Jagadeeswaran, S. Jagadeesh Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer Cancer Res 65 2005 1479 1488
7. B. Lutterbach, Q. Zeng, L.J. Davis Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival Cancer Res 67 2007 2081 2088
8. J. Bean, C. Brennan, J.Y. Shih MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 2007 20932 20937
9. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
10. L.V. Sequist, J. von Pawel, E.G. Garmey Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J Clin Oncol 29 2011 3307 3315
11. D.R. Spigel, T.J. Ervin, R. Ramlau Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC J Clin Oncol 29 Suppl 2011 Abstract 7505
12. Fournel M, Dupont I, Bonfils C, et al. Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in phase II clinical development, in combination with an EGFR inhibitor. Presented at: AACR 101st Annual Meeting; April 12-17, 2010; Washington, DC. Abstract 3612.
13. Mark M, Zhang Y-W, Su Y, et al. Combination efficacy with MetMAb and erlotinib in a NSCLC tumor model highlight therapeutic opportunities for c-Met inhibitors in combination with EGFR inhibitors. Presented at: AACR 99th Annual Meeting; April 12-16, 2008; San Diego, CA. Abstract 1336.
14. P.A. Janne, M. Wax, J.W. Leach Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design EJC Suppl 6 2008 Abstract 174
15. H.A. Wakelee, S.N. Gettinger, J.A. Engelman A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC) J Clin Oncol 28 Suppl 2010 Abstract 3017
16. Goldman JW, Laux I, Chai F, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer [Epub ahead of print].
17. L.S. Rosen, N. Senzer, T. Mekhail A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors Clin Cancer Res 17 2011 7754 7764
18. T.A. Yap, D. Olmos, A.T. Brunetto Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies J Clin Oncol 29 2011 1271 1279
19. M.S. Tsao, Y. Yang, A. Marcus Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer Hum Pathol 32 2001 57 65